内科

目的探讨亚宁定联合尼莫地平治疗高血压合并脑出血患者的疗效及对血肌酐、血钙水平的影响。方法选取2019年1月至2020年3月我院收治的高血压合并脑出血患者100例为研究对象，采用随机数字法分为两组，每组50例。两组患者均给予降颅内压、利尿脱水、神经营养支持等对症治疗。在此基础上，对照组患者给予亚宁定治疗，观察组患者给予亚宁定联合尼莫地平治疗，疗程2周。比较两组患者的临床治疗效果；比较两组患者治疗前后的血肌酐、血钙水平及不良反应发生情况。结果观察组患者的治疗总有效率（96.0%）显著高于对照组（84.0%），差异有统计学意义（P＜0.05）。治疗前，两组患者的血肌酐、血钙水平比较差异无统计学意义（P＞0.05）。治疗2周后，两组患者的血肌酐水平均显著降低，观察组患者的水平显著低于对照组；两组患者的血钙水平均显著升高，观察组患者的水平显著高于对照组，差异有统计学意义（P＜0.05）。治疗期间，两组患者的不良反应发生率比较差异无统计学意义（P＞0.05）。结论亚宁定联合尼莫地平治疗高血压合并脑出血患者的临床效果确切，能有效降低患者血肌酐水平、提高血钙水平。

ObjectiveTo investigate the therapeutic effect of urapidil hydrochloride combined with nimodipine and its effects on serum creatinine and serum calcium in patients with hypertension combined with cerebral hemorrhage. MethodA total of 100 patients with hypertension combined with cerebral hemorrhage admitted to our hospital from January 2019 to March 2020 were selected as the research objects, and they were divided into two groups by the random number method, with 50 cases in each group. Both groups were given symptomatic treatments such as intracranial pressure reduction, diuresis dehydration, and neurotrophic support, based on which the control group was treated with urapidil hydrochloride, whereas the observation group was treated with urapidil hydrochloride combined with nimodipine, for a two-week treatment course. The clinical therapeutic effects, the levels of serum creatinine, serum calcium before and after treatment, and the occurrence of adverse reactions between the two groups were compared. ResultsThe total effective rate of the observation group (96.0%) was significantly higher than that of the control group (84.0%), with a statistically significant difference (P＜0.05). Before treatment, there were no statistically significant differences in serum creatinine and calcium levels between the two groups (P＞>0.05). After 2 weeks of treatment, the serum creatinine levels of the two groups significantly decreased, and the level of the observation group was significantly lower than that of the control group. The serum calcium levels of the two groups significantly increased, and the level of the observation group was significantly higher than that of the control group, with a statistically significant difference (P＜0.05). During the treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). ConclusionThe clinical effect of urapidil hydrochloride combined with nimodipine in the treatment of patients with hypertension combined with cerebral hemorrhage is definite, which can effectively decrease the levels of serum creatinine and increase serum calcium.